Vonafexor in Patients With Impaired Renal Function and Suspected MASH (Metabolic Dysfunction-associated Steatohepatitis)

This study is testing a drug called vonafexor for people who have both impaired kidney function and suspected MASH (metabolic dysfunction-associated steatohepatitis — a form of fatty liver disease that causes inflammation and scarring). MASH is increasingly common in people with obesity and diabetes, and there are few approved treatments. **You may be eligible if...** - You are between 18 and 75 years old - You are overweight or obese (BMI 25–45) - Your kidney function is reduced but not severely so (eGFR 30–90) - You have signs of mild-to-moderate liver scarring based on specific blood tests - You may have type 2 diabetes with controlled blood sugar levels **You may NOT be eligible if...** - You have known liver disease other than fatty liver (MASH) - You have cirrhosis (advanced liver scarring) or signs of liver failure - You have lost more than 5% of your body weight in the last 6 months - You are pregnant or breastfeeding - You have had a severe allergic reaction to drugs or foods in the past - You have recently participated in another clinical trial Talk to your doctor to see if this trial is right for you.